Compare ALX & CDNA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | ALX | CDNA |
|---|---|---|
| Founded | 1928 | 1998 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Real Estate Investment Trusts | Medical Specialities |
| Sector | Real Estate | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.1B | 1.0B |
| IPO Year | 1994 | 2007 |
| Metric | ALX | CDNA |
|---|---|---|
| Price | $250.27 | $16.54 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 7 |
| Target Price | N/A | ★ $27.33 |
| AVG Volume (30 Days) | 56.7K | ★ 551.4K |
| Earning Date | 01-01-0001 | 05-13-2026 |
| Dividend Yield | ★ 7.32% | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ 5.50 | N/A |
| Revenue | ★ $213,183,000.00 | $48,324,000.00 |
| Revenue This Year | N/A | $15.37 |
| Revenue Next Year | N/A | $11.23 |
| P/E Ratio | $44.72 | ★ N/A |
| Revenue Growth | N/A | ★ 18.93 |
| 52 Week Low | $189.05 | $10.96 |
| 52 Week High | $260.84 | $21.49 |
| Indicator | ALX | CDNA |
|---|---|---|
| Relative Strength Index (RSI) | 61.29 | 31.50 |
| Support Level | $229.52 | $14.09 |
| Resistance Level | $260.04 | $17.09 |
| Average True Range (ATR) | 8.12 | 0.83 |
| MACD | 1.02 | -0.23 |
| Stochastic Oscillator | 89.87 | 4.91 |
Alexander's Inc is a real estate investment trust engaged in leasing, managing, developing and redeveloping its properties. It has six properties in the greater New York City metropolitan area. All of the revenues come from properties located in New York City which include revenues from leasing of space to tenants at their properties and revenues from parking and tenant services.
CareDx Inc operates as a precision medicine company focused on the discovery, development, and commercialization of clinically differentiated, high-value healthcare solutions for transplant patients and caregivers. It offers testing services, products, and digital solutions along with the pre- and post-transplant patient journey and is a provider of genomics-based information for transplant patients. The Company's commercially available testing services consist of AlloSure Kidney, AlloMap Heart, AlloSure Heart, a dd-cfDNA solution for heart transplant patients, and AlloSure Lung, a dd-cfDNA solution for lung transplant patients. Geographically the company generates the majority of its revenue from the United States. The company generates the majority of revenue from the Testing services.